IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

PHASE2TerminatedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

January 26, 2024

Study Completion Date

May 29, 2024

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

IMCY-0098 450 μg

Small synthetic peptide for SC admin. Solvent: alum hydroxide

DRUG

IMCY-0098 1350 μg

Small synthetic peptide for SC admin. Solvent: alum hydroxide

DRUG

Placebo

Solvent: alum hydroxide

Trial Locations (29)

35205

University of Alabama at Birmingham, Birmingham

60637

University of Chicago, Chicago

80045

Barbara Davis Center, Aurora

02215

Joslin Diabetes Center, Boston

Unknown

Princess Alexandra Hospital, Brisbane

Royal Melbourne Hospital, Melbourne

St. Vincent's Hospital, Melbourne

Royal North Shore Hospital, Sydney

Université Libre de Bruxelles - Hôpital Erasme - ULB, Brussels

UZ Brussels, Brussels

Katholieke Universiteit Leuven UZ Gasthuisberg, Leuven

Ospedale San Raffaele S.r.l., Milan

AOU Pisana - Ospedale Cisanello, Pisa

Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas

Klaipeda university hospital, Klaipėda

Vilnius university hospital Santaros klinikos, Vilnius

UMC - University Children's Hospital, Ljubljana

Department of clinical sciences, CRC/Malmö, Lund University, Lund

Addenbrooke's Hospital, Cambridge

University Hospital of Wales, Cardiff

Royal Infirmary of Edinburgh, Edinburgh

Royal Devon and Exeter Hospital, Exeter

St James´s University Hospital, Leeds

Leicester General Hospital, Leicester

Guy's and St Thomas' Hospital, London

Royal London Hospital, London

St George's Hospital, London

Royal Victoria Infirmary, Newcastle

Churchill Hospital, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Imcyse SA

INDUSTRY

NCT04524949 - IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) | Biotech Hunter | Biotech Hunter